Navigation Links
PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
Date:9/26/2008

t only our third generation rPA vaccine candidate, but also our novel second generation rPA anthrax vaccine, SparVax(TM) which is positioned for near-term procurement consideration. As previously disclosed on July 31, 2008, we submitted our response to a request for proposals to the Department of Health and Human Services (DHHS) for SparVax(TM). The solicitation outlined a requirement to procure 25 million doses of a second generation rPA anthrax vaccine intended for inclusion in the Strategic National Stockpile. We were notified by DHHS recently that our proposal was technically acceptable and within the competitive range. The second generation rPA vaccine market represents another significant opportunity for PharmAthene, with a total potential contract award of between $350 million and $600 million. We are confident in the Company's competitive prospects for this award, which DHHS has stated should be announced by year-end 2008."

About Anthrax

Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis and has the potential to be used as a weapon of bioterror when delivered in an aerosolized form. Following germination of the spores, the bacteria replicates and produces three toxins. Anthrax Protective Antigen (PA) initiates the onset of the illness by attaching to cells in the infected person where it then facilitates entry of the two additional destructive toxins -- Lethal Factor and Edema Factor, into the cell.

Antibiotics are the first line of defense against anthrax infection. However, early identification and treatment are critical for successful outcome. Even with aggressive antibiotic therapy, five of the eleven victims of the 2001 anthrax postal attacks died, underscoring the need for improved vaccines and anti-toxins for the civilian population.

About SparVax(TM) and the Third Generation Anthrax Vaccine

SparVax(TM) is a novel second generation recombinant protective (rPA) anthrax vacc
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
2. PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
3. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
4. PharmAthene Reports Second Quarter 2008 Financial and Operational Results
5. Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
6. PharmAthene Appoints Jordan P. Karp, J.D. Senior Vice President and General Counsel
7. PharmAthene Reports First Quarter 2008 Financial Results
8. PharmAthene to Host First Quarter 2008 Conference Call and Webcast on Tuesday, May 13, 2008
9. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
10. PharmAthene Reports Year-End 2007 Financial Results
11. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Although most natural and synthetic processes prefer to ... potential or energyit is within the realm of ... experience constant changes in energy and phases, such ... These conditions allow humans to regulate their body ... rumble with seismic activity. , But even ...
(Date:7/24/2014)... July 24, 2014 Research and Markets ... Genomics and Proteomics Analytical Instruments Market 2014-2018" report ... Genomics is the study of the ... of the structure and functions of proteomes or sets ... and technology. Genomics involves the mapping of genes and ...
(Date:7/24/2014)... 2014 SRI International has been awarded a ... of Allergy and Infectious Diseases (NIAID), part of the ... potential therapies for HIV infection and AIDS. The contract ... AIDS and the complications and opportunistic infections associated with ... transmission of HIV. According to the ...
(Date:7/24/2014)... Francisco, CA (PRWEB) July 24, 2014 ... to be semi-finalists in Livestrong’s Big C Competition. Out ... Health are each headed to the semi-final round. In ... Livestrong’s exclusive three-month accelerator program, complete with mentoring from ... , As part of the angelMD commitment to ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 33 angelMD Startups Make Livestrong Big C Semi-finals 2
... /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ("China Sky ... CSKI ), a leading,fully integrated pharmaceutical company producing ... today announced that the Company,s,Chief Financial Officer, Mr. ... at the upcoming Roth 21st Annual OC Growth ...
... COTTAGE, N.Y., Feb. 5 XTL,Biopharmaceuticals Ltd. (Nasdaq: ... February 3, 2009 the Company received a letter from ... outstanding ordinary shares requesting the,convening of an extraordinary shareholders, ... address and approve the following matters: , ...
... Va., Feb. 5, 2009 AMERIGROUP Chairman and Chief ... on legislation expanding the State Children,s Health Insurance Program ... of America,s children deserve a healthy start in life, ... see a family doctor and get the healthcare they ...
Cached Biology Technology:China Sky One Medical, Inc. CFO to Present at Roth Conference 2China Sky One Medical, Inc. CFO to Present at Roth Conference 3Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders' Meetings after Receipt of Shareholder Letter 2AMERIGROUP Praises Expansion of State Children's Health Insurance Program (SCHIP) 2
(Date:7/25/2014)... For the first time, Spanish researchers have detected an ... coli cells are introduced into a droplet of ... the sodium chloride crystallisation to create biomineralogical biosaline 3D ... rehydrating the material, bacteria are revived. The discovery was ... made the cover of the Astrobiology journal ...
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... for the body to make estrogen, are no longer a ... Ghosh lab at the Hauptman-Woodward Medical Research Institute (HWI) in ... three-dimensional structure of aromatase is the first time that scientists ... In fact, the Ghosh lab has determined the ...
... shows the resistance of the avian flu virus to a ... selection, with researchers documenting the trend in more than 30 ... Influenza A subtype dubbed H5N1, is evolving a resistance to ... two classes of antiviral drugs used to prevent and treat ...
... drug therapy called fenobam has shown promising initial results and ... with Fragile X syndrome (FXS). Findings of the open ... and the University of California, Davis, Medical Center are to ... Journal of Medical Genetics . Results of ...
Cached Biology News:HWI scientist first in world to unravel structure of key breast cancer target enzyme 2HWI scientist first in world to unravel structure of key breast cancer target enzyme 3Avian flu becoming more resistant to antiviral drugs, says University of Colorado study 2Avian flu becoming more resistant to antiviral drugs, says University of Colorado study 3Promising new drug being evaluated as possible treatment option for fragile X syndrome 2
... CL3 series is designed to enhance ... clinical applications at a reasonable cost. ... quick connect rotors and various biocontainment ... interface allows you to control and ...
... tradition of progressive centrifuge design and manufacturing, ... Centra-CL3 and Centra-CL3R (refrigerated) general purpose models ... Quality Control Over Sample Preparation , The ... to 99 protocols and has speed and ...
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
... DNA Polymerase I Large (Klenow) Fragment, ... that lacks both the 5´→3´ and the ... coli DNA Polymerase I (1,2). It is ... in strand displacement amplification (5). Klenow Fragment, ...
Biology Products: